Background/Aims: Tumor-infiltrating fibroblasts are a heterogeneous population, and different subpopulations play differential roles in tumor microenvironment. However, the prognostic role of podoplanin + fibroblasts in human solid tumors still remains controversial. Therefore, we performed the meta-analysis to better understand the role of this subpopulation in prognosis prediction for patients with solid tumor. Methods: We searched PubMed and EBSCO to identify the studies evaluating the association of intratumoral podoplanin + fibroblast density detected by immunohistochemical method and overall survival (OS) and/or diseasefree survival (DFS) in patients with solid tumor, then computed extracted data into hazard ratios for OS, DFS and clinicopathological features with STATA 12.0. Results: A total of 4883 patients from 29 published studies were incorporated into this meta-analysis. We found that podoplanin + fibroblast infiltration significantly decreased OS and DFS in all types of solid tumors. In stratified analyses, podoplanin + fibroblast infiltration was significantly associated with worse OS in cholangiocarcinoma, breast, lung and pancreatic cancer. And these cells were inversely associated with DFS in breast, lung and pancreatic cancer. In addition, high density of these cells significantly correlated with unfavorable clinicopathological features such as lymph node metastasis, TNM stage, lymphatic and vascular invasion of solid tumor. Conclusion: Podoplanin + fibroblast infiltration leads to worse clinical outcome in solid tumors, implicating that it is a valuable prognostic biomarker and targeting it may have a potential for effective treatment.
Introduction
Accumulating evidence has demonstrated that tumor-infiltrating fibroblasts were significantly associated with survival of solid tumors. However, they are a heterogeneous population, thus, it is important to distinguish among different subpopulations of them as they may play differential roles in tumor microenvironment (TME) [1] . Podoplanin + fibroblasts, a new subpopulation of fibroblasts identified recently, have been demonstrated to play specific and significant roles in a number of human solid tumors.
Podoplanin, a well-conserved, mucin-type transmembrane protein, has exerted a variety of functions including regulation of organ development and cell motility [2] . Recent studies have indicated that podoplanin was upregulated in fibroblasts in the tumor stroma [3] . Podoplanin + fibroblasts are often among the early immune cells recruited to tumor sites in response to the stimuli and increase in the TME. In the past decades, multitudinous studies have associated tumor-infiltrating podoplanin + fibroblasts and prognosis in patients with solid tumor, but their results were controversial [4] . Thus, it needs in-depth assessment. Furthermore, the potential of these cells as a prognostic biomarker and targeted immunotherapy is essential to be explored.
We performed this meta-analysis to clarify the association between the infiltration of podoplanin + fibroblasts and outcomes such as overall survival (OS) and disease-free survival (DFS) in breast cancer patients. 
Materials and Methods

Search strategy
Inclusion and exclusion criteria
In this meta-analysis, the inclusion criteria were: studies must have (1) been published as original articles; (2) investigated human subjects with solid tumor; (3) measured podoplanin + fibroblasts in primary tumor specimens with immunohistochemistry (IHC); (4) provided hazard ratios (HRs) with 95% confidence interval (CI), or Kaplan -Meier curves of high and low podoplanin + fibroblast density with OS, and/or DFS; (5) been published in English.
The exclusion criteria were: studies (1) were not published as research articles or full texts including commentary, case report, letters to editors and conference abstracts; (2) didn't provide sufficient data to estimate HRs; (3) detected fibroblasts not with marker 'podoplanin', or in metastatic tissues.
Endpoints
In this study, we recorded OS and DFS as the primary and second endpoint respectively.
Data extraction
Two authors (GM.H. and W.C.) independently reviewed and extracted data such as first author's name, publication year, number of patients, median age, time of follow-up, method applied to quantify podoplanin + fibroblasts, and cut-off value to determine high density of these cells. OS, DFS and clinicopathological data including Tumor, Lymph Node, Metastasis (TNM) stage, lymphatic invasion etc were extracted from the text, tables, or Kaplan -Meier curves. 
Quality assessment
Two independent authors evaluated the quality of included cohort studies with Newcastle-Ottawa Scale (NOS) [5] and achieved consensus for each item under the help of third author. A total score of 6 or more points was considered high quality.
Statistical Analysis
We combined extracted data into meta-analyses with STATA 12.0 analysis software (Stata Corporation, College Station, TX, USA). Statistical heterogeneity was evaluated by the chi-squared based Q-test or I 2 method [6] . Data were combined according to the random-effect model in the presence of heterogeneity [7] otherwise, the fixed-effect model was applied [8] . Sensitivity analysis, Begg's funnel plot and Egger's test [9] were adopted to investigate the influence of each study on the pooled result and potential publication bias respectively. All P values were two-sided and less than 0.05 are considered statistically significant.
Results
Search results and description of studies 10694 records were retrieved and the results were exhibited in Fig. 1 . We ultimately identified 29 studies containing 4883 patients with solid tumor for the assessment of intratumoral podoplanin + fibroblasts and then evaluated all these studies with the Newcastle-Ottawa Scale (NOS). Characteristics of included studies that were in accordance with the inclusion criteria and suitable for data consolidation were shown in Table 1 .
Meta-analyses Overall survival (OS).
The meta-analysis showed that podoplanin + fibroblast infiltration was significantly associated with decreased OS (HR = 1.77, 95% CI 1.42 to 2.20, P < 0.001) in patients with solid tumor (Fig. 2) . In stratified analyses according to cancer types, as shown in Fig. 3 , pooled results indicated that elevated density of podoplanin + fibroblasts was significantly associated with worse OS in breast cancer (BC) (HR = 2.46, 95% CI 1.73 to 3.50, P < 0.001), with no heterogeneity detected (I 2 = 0%, P = 0.840); Similar results were observed between increased density of these cells and OS in lung cancer (LC) (HR = 1.68, 95% CI 1.18 to 2.41, P = 0.004), pancreatic cancer (PC) (HR = 2.20, 95% CI 1.40 to 3.46, P = 0.001), and cholangiocarcinoma (CC) (HR = 1.92, 95% CI 1.11 to 3.32, P = 0.019). However, there was no significant association between podoplanin + fibroblast infiltration and OS in esophageal carcinoma (EC) (HR = 1.58, 95% CI 0.89 to 2.81, P = 0.116). 
Disease-free survival (DFS)
Meta-analysis showed that podoplanin + fibroblast infiltration significantly decreased DFS (HR = 1.74, 95% CI 1.25 to 2.42, P = 0.001) in solid tumors (Fig. 4) . In stratified analyses by cancer types, we found that increased density of podoplanin + fibroblasts within tumor was significantly associated with worse DFS in BC (HR = 2.26, 95% CI 1.56 to 3.28, P < 0.001), with little heterogeneity existing among included studies (I 2 = 6.1%, P = 0.362). Similar results were observed between podoplanin + fibroblast infiltration and DFS in LC (HR = 1.87, 95% CI 1.07 to 3.26, P = 0.027) and PC (HR = 1.97, 95% CI 1.37 to 2.84, P = 0.000); whereas there was no significant association between podoplanin + fibroblast infiltration and DFS in CRC (HR = 0.33, 95% CI 0.06 to 1.81, P = 0.203) (Fig. 5) . Table 1 . Main characteristics of the included studies In addition, we found that increased density of these cells was significantly associated with clinicopathological features including lymph node metastasis (OR = 1.47, 95% CI 1.12 to 1.92, P = 0.005), TNM stage (OR = 0.53, 95% CI 0.30 to 0.94, P = 0.030), lymphatic invasion (OR = 1.93, 95% CI 1.13 to 3.29, P = 0.016) and vascular invasion (OR = 3.00, 95% CI 1.34 to 6.70, P = 0.007), but not with primary tumor stage (OR = 1.32, 95% CI 0.46 to 3.78, P = 0.601) or tumor differentiation (OR = 0.54, 95% CI 0.25 to 1.18, P = 0.124) of patients. 
Sensitivity analysis. Sensitivity analysis showed that each included study had no influence on the overall HR for OS or DFS.
Publication bias. There was no publication bias between tumor-infiltrating podoplanin + fibroblasts and OS (P = 0.965) or DFS (P = 0.387) in patients according to the Funnel plot and Egger's test.
Discussion
Fibroblasts are traditionally implicated and well recognized in wound healing and tissue fibrosis. In the past decades, although many studies have correlated tumor-infiltrating podoplanin + fibroblasts and prognosis of solid tumors, their results were not consistent even controversial. In the present meta-analysis, we found that podoplanin + fibroblast infiltration had a negative prognostic effect associated with survival in solid tumors especially in BC, LC, PC and CC. In addition, increased density of these cells was significantly associated with lymph node metastasis, TNM stage, lymphatic and vascular invasion of solid tumor. Hence, we think these findings provide meaningful statistical evidence to exhibit the negative prognostic role of these cells in human solid tumors.
The following reasons could possibly be responsible for the close association between increased tumor-infiltrating podoplanin + fibroblasts and worse outcome of patients presented in this study: Fibroblasts in the TME are able to promote tumor cell invasion, proliferation and survival through releasing growth factors, cytokines [39] and extracellular matrix-degrading proteases such as matrix metalloproteinases (MMPs) (e.g. MMP1) [40] . More importantly, podoplanin expressed in fibroblasts can enhance the ability of these cells to promote motility and survival of neighboring cancer cells [41] . Podoplanin + fibroblasts within tumor can secret angiogenic factors including IL-8 and TNF-α as well as VEGF which promote the formation of blood vessels thereby facilitating tumor growth [42] . In addition, they can also inhibit antitumor immunity via producing amount of immunosuppressive cytokines such as TGF-β1 and IL-10 [42] and decrease the activation of effector immune cells such as CD8 + T cells through their acquisition of adhesion molecules [43] thereby establishing an immunosuppressive microenvironment. Hence, we can deduce that the tumor-infiltrating podoplanin + fibroblasts are able to promote tumor progression therefore decreasing survival.
There were some limitations in this study. First, morphometric analyses for podoplanin + fibroblasts used in individual included studies were not consistent. In addition, studies with negative results may not be published, which can cause potential publication bias.
Conclusion
In conclusion, podoplanin + fibroblast infiltration leads to an unfavorable clinical outcome of patients with solid tumor, implicating that it is a valuable prognostic biomarker and targeting it may have a potential for effective treatment.
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